Here are relevant reports on : stem-cell-therapy-market
-
Tissue Engineering Market by Product (Scaffolds (Collagen, Stem Cell), Tissue Grafts (Allograft, Autograft, Xenograft)), Material (Biological, Synthetic), Application (Orthopedics, Dermatology, Wound Care, Cardiovascular) - Global Forecast to 2028
The global tissue engineering market, valued at US$4.3 billion in 2022, stood at US$4.4 billion in 2023 and is projected to advance at a resilient CAGR of 15.3% from 2023 to 2028, culminating in a forecasted valuation of US$8.9 billion by the end of the period. The growth of this market is largely driven by the emergence of promising technologies, including 3D bioprinting, and rising demand for advanced solutions for damaged tissue repair and regeneration.
- Published: December 2023
- Price: $ 4950
- TOC Available:
-
Apoptosis Assays Market by Product (Caspase, Annexin V, DNA Fragmentation, Mitochondrial Assay), Detection Technology (Flow Cytometry, Florescence microscopy), Application (Stem Cell, Discovery & Development, Clinical Research) & Region - Global Forecasts to 2023
The global apoptosis assays market is projected to reach USD 5.9 billion by 2023, at a CAGR of 10.5%. The prominent players in the apoptosis assays market are Merck KGaA (Germany), Thermo Fisher Scientific (US), Bio-Rad Laboratories (US), Becton, Dickinson and Company (US), GE Healthcare (US), Sartorius AG (Germany), Danaher Corporation (US), Geno Technology (US), GeneCopoeia, Inc. (US), Bio-Techne Corporation(US), BioTek Instruments (US), PerkinElmer (US), Promega Corporation (US), Biotium (US), Abcam plc (UK), Canvax (Spain), Abnova (Taiwan), and Creative Bioarray (US).
- Published: November 2018
- Price: $ 4950
- TOC Available:
-
Autologous Stem Cell & Non-stem Cell Therapies Market by Type (CAR-T, Tumor Infiltrating Lymphocyte), Indication (Cancer, Musculoskeletal, Dermatology), Source (T-Cells, Mesenchymal Stem Cell), End User (Hospital) & Region - Global Forecast to 2029
The global autologous stem cell & non-stem cell therapies market, valued at US$3.9 billion in 2023, stood at US$5.5 billion in 2024 and is projected to advance at a resilient CAGR of 32.3% from 2024 to 2029, culminating in a forecasted valuation of US$22.2 billion by the end of the period. The major factors driving the growth of this market are the rising regulatory approvals for autologous CAR T cell therapies, increasing R&D investments in autologous therapeutics, and growing demand for personalized medicines.
- Published: June 2024
- Price: $ 4950
- TOC Available:
-
Leukapheresis Market by Type (Filter, Membrane Separator, Centrifugal Device), Leukopak (Mobilized, Isolated PBMC), Application (Research [Cell & Gene Therapy, Transplantation], Therapeutic), Indication, End User, Region - Global Forecast to 2031
The global Leukapheresis market, valued at USD 83.3 billion in 2025, stood at USD 90.6 billion in 2026 and is projected to advance at a resilient CAGR of 8.9% from 2026 to 2031, culminating in a forecasted valuation of USD 138.7 billion by the end of the period. This growth is driven by the increasing number of therapeutic and manufacturing applications for leukapheresis in hematologic disorders, as well as the rising demand for high-quality starting materials used in cell and gene therapy, including CAR-T, TCR, and NK-cell programs.
- Published: May 2026
- Price: $ 4950
- TOC Available:
-
Continuous Bioprocessing Market by Product (Chromatography, Filtration, Bioreactor, Media), Process (Upstream, Downstream), Scale of Operation (Commercial, Clinical), Application (mAbs, Vaccines, Cell & Gene Therapy), & End User - Global Forecast to 2028
The global continuous bioprocessing market, valued at US$201 million in 2022, stood at US$218 million in 2023 and is projected to advance at a resilient CAGR of 22.4% from 2023 to 2028, culminating in a forecasted valuation of US$599 million by the end of the period. The growth of the market is largely driven by rising demand for biopharmaceuticals, advantages of continuous bioprocessing over batch/fed-batch mode, and emergence of integrated end-to-end continuous bioprocessing.
- Published: November 2023
- Price: $ 4950
- TOC Available:
-
Recombinant Proteins Market by Product (Growth Factors, Chemokines, Structural Proteins, Membrane Proteins), Application (Drug Discovery & Development (Biologics, Vaccines, Cell & Gene Therapy), Research, Biopharma Production) & Region - Global Forecast to 2028
The global recombinant proteins market, valued at US$2.1 billion in 2022, stood at US$2.2 billion in 2023 and is projected to advance at a resilient CAGR of 7.2% from 2023 to 2028, culminating in a forecasted valuation of US$3.2 billion by the end of the period. Growth in the market can be attributed to factors such as rising incidence of chronic diseases, growing demand for biologics and biosimilars due to expiration of patents, rising demand for customized medicine and increasing government initiatives for R&D in life sciences research.
- Published: January 2024
- Price: $ 4950
- TOC Available:
-
Viral Vector & Plasmid DNA Manufacturing Market by Type (Viral Vector (Retroviruses, Adenoviruses, AAV, Lentiviruses), Plasmid DNA), Workflow (Upstream, Downstream), Application (Cell & Gene Therapy), Diseases (Cancer), End User - Global Forecast to 2028
The global viral vector manufacturing market, valued at US$4.8 billion in 2022, stood at US$5.5 billion in 2023 and is projected to advance at a resilient CAGR of 18.2% from 2023 to 2028, culminating in a forecasted valuation of US$12.8 billion by the end of the period. The growth of this market is majorly driven by g rising prevalence of target diseases and disorders, the availability of funding for gene therapy development, and effectiveness of viral vectors in gene therapy delivery.
- Published: June 2023
- Price: $ 4950
- TOC Available:
-
CAR T-Cell Therapy Market by Product (Abecma, Breyanzi, Carvykti, Yescarta, Tecartus, Kymriah), Target (CD19, BCMA), Indication (Multiple Myeloma, Leukemia, Lymphoma), Demographic (Adult, Pediatric), Region, Competitive Landscape - Global Forecast to 2031
The global CAR T-cell therapy market, valued at USD 5.98 billion in 2025, stood at USD 6.78 billion in 2026 and is projected to advance at a resilient CAGR of 14.9% from 2026 to 2031, culminating in a forecasted valuation of USD 13.56 billion by the end of the period. The global CAR T-cell therapy market is growing due to rapid technological advances alongside rising investments from large pharma and well-funded biotech's.
- Published: February 2026
- Price: $ 4950
- TOC Available:
-
Cardiac Resynchronization Therapy Market by Product Type (Cardiac Resynchronization Therapy Defibrillator and Cardiac Resynchronization Therapy Pacemaker), End User (Hospitals & Cardiac Centers and Ambulatory Surgery Centers) & Region - Global Forecasts to 2024
The cardiac resynchronization therapy market is projected to reach USD 5.1 billion by 2024, at a CAGR of 4.4%. The growth of the Cardiac Resynchronization Therapy Market is majorly driven by the increasing incidence of target diseases (primarily due to the rising geriatric population). Rising investments and support, along with technological advancements, are also contributing to the growth of this market. Prominent players in the Cardiac Resynchronization Therapy Market are Medtronic (Ireland), Abbott (US), Boston Scientific Corporation (US), MicroPort Scientific Corporation (China), BIOTRONIK (Germany), and Medico S.p.A. (Italy).
- Published: April 2019
- Price: $ 4950
- TOC Available:
-
Induced Pluripotent Stem Cells Market - Global Forecasts to 2023
The global Induced Pluripotent Stem Cells Market is estimated to be valued at USD 1,245.0 million in 2017 and is projected to reach 1,829.3 million by 2023 at a rate of 8.0%. The iPSC market is broadly segmented into hepatocytes, fibroblasts, keratinocytes, amniotic cells, and other cell types. The global induced pluripotent stem cells market is developing rapidly. The primary reason for inclination toward usage of induced pluripotent stem cells is their ability to make any cell or tissue required by the body to defend or combat diseases such as leukemia, spinal cord injury, heart disease, and diabetes. Another advantage is that iPSCs can be created from the tissue of the same patient that will receive the transplantation, thus avoiding immune rejection. Other factors supporting the growth of the market are the increased research funding, growth in number of genomics projects, and increasing use of genome engineering in personalized medicine. However, adverse public of genetic research is likely to restrain the growth of the market.
- Published: June 2026
- Price: $ 4950
- TOC Available:
Records 21 to 30 of 50
